HEFFX Initiates Coverage on Nutra Pharma Corp. (OTCMKTS:NPHC)
On the surface this one looks interesting and we will be digging around to see if NPHC represents an opportunity or is just another sub-penny shocker.
Nutra Pharma Corp. is a biopharmaceutical company. The Company is engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies, as well as homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, autoimmune and infectious diseases. The Company’s subsidiary and drug discovery arm, ReceptoPharm, Inc. (ReceptoPharm), carries its homeopathic and drug discovery research and clinical development and has developed homeopathic drugs for the treatment of pain: Cobroxin, an over-the-counter pain reliever designed to treat moderate to severe (Stage II) chronic pain; Nyloxin and Nyloxin Extra Strength, stronger versions of Cobroxin, and Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs. It has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases, and RPI-MN, to treat viral diseases.
Over-the-counter (OTC) pain medications should be the first choice when trying to tolerate chronic pain. Ultra-addictive, narcotic pain medications produced by big pharma companies are so rampant in today’s world. Nutra Pharma Corp. (OTCQB: NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma’s intellectual property portfolio is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
NUTRA PHARMA CRP closed up 0.001 at 0.008. Volume was 86% below average (consolidating) and Bollinger Bands were 26% narrower than normal.
Open High Low Close Volume___
0.008 0.008 0.008 0.008 48,150
Short Term: Neutral
Intermediate Term: Bullish
Long Term: Bearish
Moving Averages: 10-period 50-period 200-period
Close: 0.01 0.01 0.04
Volatility: 186 249 251
Volume: 338,182 383,208 347,712
Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.
NUTRA PHARMA CRP is currently 80.7% below its 200-period moving average and is in an upward trend. Volatility is Our volume indicators reflect volume flowing into and out of NPHC.PK at a relatively equal pace (neutral). Our trend forecasting oscillators are currently bullish on NPHC.PK and have had this outlook for the last 17 periods.
Latest posts by Shayne Heffernan (see all)
- Wesfarmers Ltd (ASX:WES) Downgraded as Company Turns Political - January 19, 2017
- Pauline Hanson: Halal Certification at Best a Scam at Worst Funding Terrorism - January 19, 2017
- Hong Kong Racing: Hong Kong Classic Mile - January 19, 2017